Biogen

Biogen Idec Blood Disorder Drug Registers Positive Outcomes for Phase 3 Trials

Biogen Idec Blood Disorder Drug Registers Positive Outcomes for Phase 3 Trials

Biogen Idec and Swedish Orphan Biovitrum AB have registered positive outcomes for phase 3 trials of experimental drug for hemophilia A. The clinical trial has found high success rate among children suffering from blood disorder in maintaining low bleeding rates.

Biogen Idec announced that the experimental drug ELOCTATE was tested for efficacy and safety in the clinical trial carried out of children under 12 years of age. Swedish Orphan Biovitrum developed using Fc fusion process. The drug claims to prolong the circulation of infused clotting factor.

Location: 
Company: 

FDA Approves Biogen’s Hemophilia B Drug, Alprolix

FDA Approves Biogen’s Hemophilia B Drug, Alprolix

U.S. Food and Drug Administration (FDA) has given green signal to long-lasting hemophilia B drug to treat multiple sclerosis by Biogen Idec Inc. The company said that the drug has Factor IX molecule which makes the product last longer in circulation.

The drug, Alprolix, developed by collaboration of Biogen and Swedish Orphan Biovitrum AB (SOBI) has been approved to treat the blood disorder. Tony Kingsley, executive vice president of Biogen’s global commercial operations, said the current treatment performs several infusions a week, but the new drug reduces the need for infusions.

Laboratories: 
Company: 

Popular Stories

Harley-Davidson to turn 8 Dyna motorbikes into new Softail bikes

Betting big on cruisers, the luxury motorcycle... Read More

Uber’s net loss declines as ride bookings grow

Uber Technologies reported lower loss by nearly 9... Read More

Samsung Galaxy Note 8 facing challenges on multiple fronts

The Samsung Galaxy Note 8 is facing an increasingly... Read More

Leaked reports reveal more about new BMW M5

Luxury carmaker BMW’s next-generation M5 car will... Read More